Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00276055 · ClinicalTrials.gov registry record · Phase 1
Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma
A Phase 1 study, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT00276055 is a Phase 1 study that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 38 participants.
The verdict
NCT00276055, a Phase 1 study, has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
1.1 To determine the recommended phase II dose for gemcitabine in combination with a fixed dose of docetaxel and bevacizumab. 1.2 To determine the efficacy of the combination of gemcitabine, docetaxel, and bevacizumab in patients with soft tissue sarcoma 1.3 To determine the toxicity profile of the combination of gemcitabine, docetaxel, and bevacizumab in patients with soft tissue sarcoma
Interventions
- DRUG Gemcitabine, Docetaxel and Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2005-11 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00276055
The ClinicalTrials.gov registry entry for NCT00276055 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine, Docetaxel and Bevacizumab is the first listed.
NCT00276055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00276055 about?
NCT00276055 is a clinical study titled "Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma". 1.1 To determine the recommended phase II dose for gemcitabine in combination with a fixed dose of docetaxel and bevacizumab. 1.2 To determine the efficacy of the combination of gemcitabine, docetaxel, and bevacizumab in patients with soft tissue sarcoma 1.3 To determine the toxicity profile of the...
What is the current status of trial NCT00276055?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2005-11. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00276055?
The interventions under investigation include: Gemcitabine, Docetaxel and Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00276055?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.